Literature DB >> 23809849

N- versus O-alkylation: utilizing NMR methods to establish reliable primary structure determinations for drug discovery.

Steven R LaPlante1, François Bilodeau, Norman Aubry, James R Gillard, Jeff O'Meara, René Coulombe.   

Abstract

A classic synthetic issue that remains unresolved is the reaction that involves the control of N- versus O-alkylation of ambident anions. This common chemical transformation is important for medicinal chemists, who require predictable and reliable protocols for the rapid synthesis of inhibitors. The uncertainty of whether the product(s) are N- and/or O-alkylated is common and can be costly if undetermined. Herein, we report an NMR-based strategy that focuses on distinguishing inhibitors and intermediates that are N- or O-alkylated. The NMR strategy involves three independent and complementary methods. However, any combination of two of the methods can be reliable if the third were compromised due to resonance overlap or other issues. The timely nature of these methods (HSQC/HMQC, HMBC. ROESY, and (13)C shift predictions) allows for contemporaneous determination of regioselective alkylation as needed during the optimization of synthetic routes.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Keywords:  Drug discovery; Medicinal chemistry; NMR; O/N alkylation; Primary structure

Mesh:

Substances:

Year:  2013        PMID: 23809849     DOI: 10.1016/j.bmcl.2013.06.007

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Synthesis and SAR studies of novel 6,7,8-substituted 4-substituted benzyloxyquinolin-2(1H)-one derivatives for anticancer activity.

Authors:  Yi-Fong Chen; Yi-Chien Lin; Susan L Morris-Natschke; Chen-Fang Wei; Ting-Chen Shen; Hui-Yi Lin; Mei-Hua Hsu; Li-Chen Chou; Yu Zhao; Sheng-Chu Kuo; Kuo-Hsiung Lee; Li-Jiau Huang
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

2.  Synthesis of O- and N-alkylated products of 1,2,3,4-tetrahydrobenzo[c][2,7]naphthyrin-5(6H)-one.

Authors:  Shobanbabu Bommagani; Na-Ra Lee; Xuan Zhang; Linda P Dwoskin; Guangrong Zheng
Journal:  Tetrahedron Lett       Date:  2015-11-18       Impact factor: 2.415

3.  Discovery of 4-alkoxy-2-aryl-6,7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in vitro anticancer activity.

Authors:  Mostafa M Elbadawi; Wagdy M Eldehna; Wenjie Wang; Keli K Agama; Yves Pommier; Manabu Abe
Journal:  Eur J Med Chem       Date:  2021-02-09       Impact factor: 7.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.